Schizophrenia is an often devastating neuropsychiatric illness. Genetic factors have been strongly implicated. The genetic contribution to schizophrenia is, however, likely to be complex and difficult to capture by merely considering sequence variation. DNA methylation studies represent a particularly promising complement for several reasons. First, as methylation is directly related to gene expression, knowledge of gene methylation levels may add to the prediction of disease status. Second, methylation studies can provide insight into phenomena such as age of onset, the episodic nature of schizophrenia, gene-environment interactions, parental effects, and sex differences. Third, methylation sites are also excellent new drug targets as they are modifiable by pharmacological interventions. Finally, methylation markers are accessible at the stable DNA level, which from a translational perspective means that they can potentially also be used in clinical settings to improve diagnosis and treatment. Methylation studies have historically been restricted to a limited number of candidate genes. However, it has recently become technically and economically feasible to measure the methylation status of millions of markers simultaneously. This resembles recent developments in genomewide association studies (GWAS), which have accelerated the discovery of disease variants considerably. To identify methylation sites related to schizophrenia, we have applied statistical theory developed by our group to determine the most cost-effective study design. Based on these optimal design calculations, we propose a whole genome methylation profiling study in 750 schizophrenia cases and 750 controls. To eliminate false discoveries due to technical and sampling errors, we will follow up the most promising sites in an independent sample of schizophrenia cases and controls using pyrosequencing. Our current power calculations suggest that we may need to follow up 65 regions in 800 cases and 800 controls. However, one strength of the statistical method we developed is that it can be used adaptively--that is, the optimal sample size and number of markers for the second pyrosequencing replication stage can be empirically determined based on parameters estimated from the first, array-based discovery stage. In order to improve our understanding of the disease mechanisms, secondary analyses will be performed relating the methylation regions to clinical information as well as to a genome-wide panel of already available SNP markers and copy number variant calls.

Public Health Relevance

Schizophrenia is an often devastating neuropsychiatric illness. DNA methylation studies represent a particularly promising complement to current genetic studies that offer great potential to improve the understanding and treatment of the disease.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
High Impact Research and Research Infrastructure Programs (RC2)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-C (A2))
Program Officer
Koester, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
Schools of Pharmacy
United States
Zip Code
Shabalin, Andrey A; Hattab, Mohammad W; Clark, Shaunna L et al. (2018) RaMWAS: fast methylome-wide association study pipeline for enrichment platforms. Bioinformatics 34:2283-2285
Hattab, Mohammad W; Shabalin, Andrey A; Clark, Shaunna L et al. (2017) Correcting for cell-type effects in DNA methylation studies: reference-based method outperforms latent variable approaches in empirical studies. Genome Biol 18:24
van den Oord, Edwin J C G; Clark, Shaunna L; Xie, Lin Ying et al. (2016) A Whole Methylome CpG-SNP Association Study of Psychosis in Blood and Brain Tissue. Schizophr Bull 42:1018-26
Clark, Shaunna L; Aberg, Karolina A; Nerella, Srilaxmi et al. (2015) Combined Whole Methylome and Genomewide Association Study Implicates CNTN4 in Alcohol Use. Alcohol Clin Exp Res 39:1396-405
McClay, Joseph L; Aberg, Karolina A; Clark, Shaunna L et al. (2014) A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjects. Hum Mol Genet 23:1175-85
Aberg, Karolina A; McClay, Joseph L; Nerella, Srilaxmi et al. (2014) Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 71:255-64
Aberg, Karolina A; Xie, Lin Y; Nerella, Srilaxmi et al. (2013) High quality methylome-wide investigations through next-generation sequencing of DNA from a single archived dry blood spot. Epigenetics 8:542-7
Aberg, Karolina A; Xie, Lin Y; McClay, Joseph L et al. (2013) Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions. Epigenomics 5:367-77
van den Oord, Edwin J C G; Bukszar, Jozsef; Rudolf, Gabor et al. (2013) Estimation of CpG coverage in whole methylome next-generation sequencing studies. BMC Bioinformatics 14:50
Chen, Wenan; Gao, Guimin; Nerella, Srilaxmi et al. (2013) MethylPCA: a toolkit to control for confounders in methylome-wide association studies. BMC Bioinformatics 14:74

Showing the most recent 10 out of 11 publications